Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018, Article ID 9157036, 3 pages
Case Report

Novel Treatment of Small-Cell Neuroendocrine of the Vagina

1Department of Obstetrics and Gynecology, Orlando Regional Healthcare, Orlando, FL, USA
2Gynecologic Oncology, Florida Hospital Medical Group, Maitland, FL, USA
3Department of Pathology, Orlando Regional Healthcare, Orlando, FL, USA

Correspondence should be addressed to S. J. Carlan; moc.liamg@nalracevets

Received 27 October 2017; Accepted 11 January 2018; Published 4 February 2018

Academic Editor: Gerassimos P. Vandoros

Copyright © 2018 Kathryn Kostamo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Primary vaginal small-cell neuroendocrine carcinoma is an extremely rare and highly aggressive malignancy. Eighty-five percent of patients die within one year of diagnosis from metastatic disease despite multimodal therapy. Gene expression profiling of tumor tissue may be useful for treatment options for various malignancies. Case. A 34-year-old nulliparous woman was diagnosed with primary vaginal small-cell neuroendocrine carcinoma. Twenty weeks after the initial visit, she was diagnosed with recurrence and started on chemoradiation based on the results of gene expression profile of tumor tissue. She died 34 months after the initial visit and had a 14-month progression-free survival (PFS). Conclusion. Gene expression profile of tumor tissue in the management of primary vaginal small-cell neuroendocrine carcinoma may be helpful in extending progression-free survival.